Why GW Pharmaceuticals (GWPH) Stock Is Up Today

NEW YORK (TheStreet) -- GW Pharmaceuticals (GWPH) shares are up 3% to $64 on Monday following the announcement that its Sativex drug treatment had received a "fast track" designation from regulators at the Food and Drug Administration.

The fast track program is designed to facilitate the development of drugs intended to treat life threatening diseases. 

Sativex, a cannaboid based treatments that is comprised of CBD (cannabidiol) and THC, is designed to treat pain associated with advanced stages of cancer. It is currently in Phase 3 clinical trials.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. 

GWPH Chart

GWPH data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months.Learn more.

More from Markets

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss